ProMIS Neurosciences (DE:23J)
FRANKFURT:23J
23J Stock Chart & Stats
€6.60
--
Market closed
€6.60
--
Day’s Range― - ―
52-Week Range€5.68 - €28.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.88K
Market Cap
€23.21M
Enterprise Value€10.36M
Total Cash (Recent Filing)€6.15M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 18, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding2,152,397
10 Day Avg. Volume100
30 Day Avg. Volume2,877
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.95Price Target Upside353.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
PIPE Financing / Extended RunwayThe $75M PIPE materially changes financing dynamics: it provides multi-year runway into 2028 and funds completion of Phase 1b, subcutaneous formulation work, and blinded 6- & 12-month readouts. That structural funding reduces near-term refinancing risk and lets management focus on clinical value creation.
Low Reported LeverageConsistently low reported debt gives the company structural flexibility: limited interest burden and simpler capital structure allow cash raised to be allocated to R&D rather than debt service, lowering bankruptcy risk and preserving optionality through lengthy clinical development cycles.
Focused R&D StrategyA concentrated scientific strategy — antibody-based candidates targeting toxic protein species in neurodegeneration — creates a clear development roadmap and potential scientific differentiation. Focused pipelines can build durable competitive advantages if clinical data validate target selection and mechanism.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow signals chronic dependence on external capital to fund operations. Over the medium term this raises dilution risk and constrains strategic choices, as future financings may be needed if clinical timelines slip or costs increase despite the recent PIPE.
Negative Shareholders' EquityRecurrent negative equity reflects accumulated losses and erodes balance-sheet resilience. This condition can limit access to conventional financing, increase cost of capital, and weaken negotiating leverage for partnerships or licensing deals, making long-term funding and growth more challenging.
No Recurring Revenue / Pre-commercial ProfileWith negligible recurring revenue, the company's prospects hinge on successful clinical outcomes and later commercialization. This binary, long-dated revenue profile increases execution risk: revenues are uncertain and distant, reducing near-term cash generation and magnifying the impact of trial setbacks.
ProMIS Neurosciences News
23J FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was €5.68 and its highest was €28.50 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is €23.21M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is May 18, 2026 which is in 34 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Mar 25, 2026. The company reported -€3.555 earnings per share for the quarter, beating the consensus estimate of -€4.03 by €0.476.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -0.92.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -€3.555 in its last earnings report, beating expectations of -€4.03. Following the earnings report the stock price went down -0.671%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in DE:23J
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
23J Stock 12 Month Forecast
Average Price Target
€29.95
▲(353.77% Upside)